Zeposia – AAN Display Banners Conference – June – 27440
AAN 2022 eBOOK: A Focus on Multiple Sclerosis
AAN 2022 MS Neurov1.indd
Read More
Social Vulnerability Predicts Greater Multiple Sclerosis Disability
“It has previously been thought that [multiple sclerosis (MS)] is less common among non-European...
Read MorePlasma NfL levels associated with cardiovascular risk
Elevated levels of neurofilament light chain (NfL) are a known biomarker for neurodegeneration in conditions such as stroke, dementia, Multiple sclerosis, and Amyotrophic lateral sclerosis. A new study reveals that NfL may also...
Read More
Long-term Ozanimod Delivers No Evidence of Disease Activity in MS
Patients with relapsing multiple sclerosis (RMS) achieved No Evidence of Disease Activity (NEDA)...
Read MoreAAN 2022 Virtual
Can’t make it to AAN in person? Don’t worry because the conference is continuing to host virtually as well. This year, the virtual conference will take place April 24-26, with access to session recordings through May...
Read MoreAAN Schedule Highlights
April 2, 7:00 PM – 10:00 PM Industry Therapeutic Update from EMD Serono, Inc.: Early DMT switch considerations in MS and discussing the capacity to mount an immune response April 3, 5:00 PM – 5:30 PM AAN Leadership...
Read MoreAAN Covid-19 Safety Protocals
Proof of Vaccination + Mask Requirement All in-person attendees, exhibitors, press personnel, guests, and staff must complete the COVID-19 vaccination process with an acceptable vaccine and booster, if eligible, a minimum of 7...
Read MoreStructural Brain Damage & Cognitive Impairment Association
In individuals with multiple sclerosis (MS), researchers sought to determine the role of cognitive dysfunction in motor disability and structural disease-related burden. About 81 healthy controls and 109 relapsing-remitting (RR)...
Read MoreRelapsing Multiple Sclerosis and its Links
In the OPTIMUM trial, researchers sought to determine disability, cognition, motor function, and multiple sclerosis (MS) fatigue in relation to baseline and change in brain volume (BV). Over the course of 108 weeks, patients...
Read MorePrognosis communication for Multiple Sclerosis Patients
For a study, the researchers sought to look at early-stage relapsing-remitting multiple sclerosis (RRMS) patients’ long-term prognosis (LTP) communication preferences and factors. A non-interventional, multicenter trial...
Read MoreKetogenic Diet as a Strategy in Relapsing Multiple Sclerosis
For a study, the researchers sought to determine the safety and tolerability of a ketogenic diet (KD) in relapsing MS patients and the influence on patient-reported, laboratory, and clinical outcome measures. Investigators...
Read MoreDisease Activity in Patients With Relapsing Multiple Sclerosis
No evidence of disease activity 3 and 4 (NEDA-3 and NEDA-4) in RMS patients treated with ozanimod were evaluated. Data were gathered from a randomized phase 3 trial (RADIANCE, NCT02047734) comparing oral ozanimod 0.92 mg/d to...
Read MorePhase 3 and Extension Trials With Ozanimod Therapy on Cortical Grey Matter Volume
The researchers evaluated the size and duration of interferon-induced changes in cortical grey matter volume (CGMV) for a study. In addition, they examined the long-term effects of switching to ozanimod in relapsing multiple...
Read MoreResponse to SARS-CoV-2 Vaccine in RMS Patients Using Ozanimod
For a study, the researchers sought to characterize antibody and T-cell responses to the 3 SARS-CoV-2 vaccinations now available in the United States (US) in patients with relapsed multiple sclerosis (RMS) who were using...
Read More